INO — what changed in the latest 10-Q
A section-by-section comparison of INO's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-12 vs the prior 10-Q · 2026-05-13
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +31 | −16 | ~18 | 29 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 2 |
| Legal proceedings | Text added/removed | +2 | −1 | ~2 | 1 |
| Risk factors | Text added/removed | +24 | −29 | ~16 | 293 |
| Other information | Text added/removed | +1 | −1 | 0 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3)
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-12
In August 2025, PAPZIMEOS, a gorilla adenoviral vector-based immunotherapy, was approved for the treatment of adults with RRP. PAPZIMEOS is administered as adjuvant treatment following surgical debulking. Unlike INO-3107, PAPZIMEOS requires additional surgery prior to its third and fourth doses if v…
In anticipation of a potential approval in 2026, we are preparing for commercial launch activities. Recently, we engaged Syneos Health to recruit and deploy Medical Science Liaisons (MSLs), and Syneos Health is also serving as our contract sales organization to support commercialization in the U.S. …
We have presented key data regarding the development of INO-3107 at several scientific conferences. Highlights from the data include:
Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2025 Annual Report and Note 2 to our audited Consolidated Financial Statements contained in our 2025 Annual Report.
Revenue. Total revenue was $0 for both the three and six months ended June 30, 2026, as compared to $0 and $65,000 for the three and six months ended June 30, 2025, respectively, all of which was derived under the collaborative arrangement with ApolloBio.
Text removed vs the prior filing · source: 10-Q · 2026-05-13
In January 2026, a new position statement was published in The Laryngoscope (S. R.Best, A. D.Friedman, C. A.Rosen, et al.,“Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP,” The Laryngoscope (2026): 1–11, https://doi.org/10.1002/lary.70379) outl…
In 2025 we presented key data regarding the development of INO-3107 at several scientific conferences. Highlights from the data include:
Revenue. Total revenue was $0 and $65,000 for the three months ended March 31, 2026 and 2025, respectively, all of which was derived under the collaborative arrangement with ApolloBio.
Contributions received from current grant agreements and recorded as contra-research and development expense were $51,000 and $286,000 for the three months ended March 31, 2026 and 2025, respectively. The decrease was primarily due to a decrease in expenses earned under the sub-grants through Wistar…
General and administrative expenses. General and administrative expenses, which include commercial, business development expenses and patent expenses, were $7.9 million and $9.0 million for the three months ended March 31, 2026 and 2025, respectively. Decreases for the three-month period year over y…
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-08-12
Between March 16 and May 27, 2026, three additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Pepito v. Shea, et al., Panes v. Shea, et al., and Ghahremani v. Shea, et al., and filed March 16, 2026, May 1, 202…
On July 22, 2026, a fifth shareholder derivative complaint was filed in the United States District Court for the District of Delaware, captioned Andrews v. Shea, et al. The Andrews complaint asserts substantially similar claims as the Shin action and names the same defendants.
Text removed vs the prior filing · source: 10-Q · 2026-05-13
On March 16, 2026, a second shareholder derivative complaint was filed in the United States District Court for the Eastern District of Pennsylvania, captioned Pepito v. Shea, et al.; and on May 1, 2026, a third shareholder derivative complaint was filed in the United States District Corut for the Ea…
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-08-12
our common stock could decline. You should also consider the more detailed description of our business contained in our 2025 Annual Report.
Our historical financial statements have been prepared under the assumption that we will continue as a going concern. As of June 30, 2026, we had an accumulated deficit of $1.8 billion and had cash, cash equivalents and short-term investments of $36.7 million. These conditions raise substantial doub…
The regulatory review and approval process, which includes evaluation of preclinical studies and clinical trials of our combination products as well as the evaluation of our device design, manufacturing processes and our third-party contract manufacturers' facilities, is lengthy, expensive and uncer…
and regulatory provisions associated with each constituent part in the FDA’s review of the combination product as a whole and its constituent parts. This includes how the constituent parts may interact and interrelate and is a complex process. To the extent that our DNA medicine candidates are manuf…
particularly given the complexity concerning the manufacturing of combination products, or uneconomical to market, or our competitors could develop superior products more quickly and efficiently or more effectively market their competing products.
Text removed vs the prior filing · source: 10-Q · 2026-05-13
Our historical financial statements have been prepared under the assumption that we will continue as a going concern. As of March 31, 2026, we had an accumulated deficit of $1.8 billion and had cash, cash equivalents and short-term investments of $37.7 million. These conditions raise substantial dou…
equivalents and short-term investments as of the filing date, May 13, 2026, together with the net proceeds of $16.0 million from the April 2026 Offering, which closed on April 6, 2026, will enable us to fund our planned operating expenses and capital expenditure requirements into the first quarter o…
our first marketed product. We may never successfully commercialize INO-3107 or our other DNA medicine candidates or proprietary device technology and thus may never have any significant future revenues or achieve and sustain profitability.
The regulatory review and approval process, which includes evaluation of preclinical studies and clinical trials of our combination products as well as the evaluation of our device design, manufacturing processes and our third-party contract manufacturers' facilities, is lengthy, expensive and uncer…
various reasons. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:
Other information
Text added vs the prior filing · source: 10-Q · 2026-08-12
During the three months ended June 30, 2026, none of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 40…
Text removed vs the prior filing · source: 10-Q · 2026-05-13
During the three months ended March 31, 2026, none of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted, modified or terminated any contracts, instructions or written plans for the purchase or sale of our securities.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice